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The first chromosomal locus for familial combined hyperlipid-
emia (FCHL) on 1q21–23 in Finnish pedigrees led to the identifi-
cation of upstream transcription factor 1 (USF1), a transcriptional 
regulator critically involved in lipid and glucose homeostasis 
[1,2]. Since this original report, association of USF1 with FCHL 
was replicated in Mex­ican Americans and Utah Caucasians [3,4] 
and subsequent studies in distinct ethnic population samples also 
linked variants in the USF1 gene to inherited susceptibility for 
hyperlipidemia, the metabolic syndrome and its component traits 
[5–7]. Importantly, in a recent prospective study, specific alleles of 
the USF1 gene proved to modify cardiovascular risk and contribute 
both to cardiovascular disease and all-cause mortality at the popu-
lation level [8].
Considerable genetic and phenotypic overlap ex­ists between 
FCHL and type 2 diabetes and dyslipidemia is a very commonly 
observed phenomenon in patients with type 2 diabetes. FCHL and 
type 2 diabetes both develop against a background of insulin resis-
tance and predispose to early cardiovascular disease. The USF1 
chromosomal region 1q21–23 has not only been repeatedly attrib-
uted to FCHL [1,9–11], but also represents the most consistently 
replicated locus in genome wide scans for linkage to type 2 dia-
betes [12–21]. USF1 is therefore an attractive biological and posi-
tional candidate gene for type 2 diabetes. Yet, the direct contribu-
tion of the USF1 gene on type 2 diabetes susceptibility has been 
addressed in a more limited fashion and results are less unequiv-
ocal than for FCHL and lipid traits. Two studies thus far reported 
a significant genetic association with type 2 diabetes or its compo-
nent traits with the same single nucleotide polymorphisms (SNPs) 
(rs2073658 and rs3737787)—or SNPs in tight LD—as identified for 
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Type 2 diabetes shares substantial genetic and phenotypic overlap with familial combined hyperlipid-
emia. Upstream stimulatory factor 1 (USF1), a well-established susceptibility gene for familial combined 
hyperlipidemia, is postulated to be such a shared genetic determinant. We evaluated two established 
variants in familial combined hyperlipidemia (rs2073658 and rs3737787) for association with type 2 
diabetes in two Dutch case-control samples (N = 2011). The first case-control sample comprised 501 
 subjects with type 2 diabetes from the Breda cohort and 920 healthy blood bank donors of Dutch Cau-
casian origin. The second case-control sample included 211 subjects with type 2 diabetes, and 379 nor-
moglycemic controls. SNP rs2073658 and SNP rs3737787 were in perfect linkage disequilibrium. In the 
first case-control sample, prevalence of the major allele was higher in patients than in controls (75% 
versus 71%, OR = 1.25, p = 0.018). A similar effect-size and -direction was observed in the second case-
control sample (76% versus 72%, OR = 1.22, p = 0.16). A combined analysis strengthened the evidence for 
association (OR = 1.23, p = 0.006). Notably, the increased risk for type 2 diabetes could be ascribed to the 
major allele, and its high frequency translated to a substantial population attributable risk of 14.5%. 
In conclusion, the major allele of rs2073658 in the USF1 gene is associated with a modestly increased risk 
to develop type 2 diabetes in Dutch Caucasians, with considerable impact at the population level.
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FCHL and lipid traits [5,6]. Data from the two most recent studies 
did not provide additional support for a statistically significant 
effect [22,23]. In order to adequately evaluate the contribution of 
USF1 risk alleles to type 2 diabetes in distinct populations and pro-
vide robust assessment of effect-size, replication studies in large, 
well-defined cohorts are required.
In the present study we investigated whether variants in the 
USF1 gene contribute to the inherited susceptibility for developing 
type 2 diabetes in 2011 subjects of the Dutch population, using two 
independent case-control samples comprising 712 patients with 
type 2 diabetes and 1299 healthy controls.
Mate­ri­als and me­th­ods
Su­b­jects
The first case-control sample comprised 501 subjects with type 2 diabetes from 
the Breda cohort [24] and 920 healthy blood bank donors of Dutch Caucasian ori-
gin [25]. Patients were diagnosed according to the WHO criteria (random plasma 
glucose level >11.1 mmol/l or a fasting plasma glucose level >7.0 mmol/l). The clin-
ical characteristics of the patients (HbA1c, total cholesterol, HDL-cholesterol and 
triglycerides) were available, as well as the level of obesity (body mass index­) in 
each individual. Clinical characteristics of the first case-control sample are provided 
in Table 1. The second case-control sample was collected as described previously 
[26,27]. Briefly, more than 2700 subjects with one or more cardiovascular risk 
factors, including hypertension, BMI > 25 kg/m2, a positive family history for type 
2 diabetes mellitus, or a history of gestational diabetes, were screened for type 2 
diabetes. Ex­clusion criteria were the use of medication that affects glucose metab-
olism and non-Caucasian ethnicity. The case-control sample comprised all newly 
diagnosed subjects with type 2 diabetes (N = 211), and a random selection of 379 
normoglycemic control subjects. Clinical characteristics of the second case-control 
sample are provided in Table 2. The Human Investigation Review Committee of the 
Academic Hospital Maastricht and the Medical Ethics Committee of the University 
Medical Center Utrecht approved the study protocol and all subjects gave written 
informed consent.
Genotypi­ng
Previous studies that investigated the genetic contribution of USF1 to FCHL 
and type 2 diabetes identified two specific SNPs—or variants in tight LD with these 
SNPs—that were consistently most strongly associated with disease. These vari-
ants, rs2073658 and rs3737787 are 1239 bp apart and located in intron 7 and the 39 
untranslated region of the USF1 gene respectively. In previous reports [2–4,22] both 
variants were in (almost) complete linkage disequilibrium.
SNPs rs2073658 and rs3737787 were genotyped using Taqman assays (Applied 
Biosystems). Assays were performed according to the manufacturer’s instructions. 
The DNA samples were processed in 384-well plates. Each plate contained eight 
negative controls and 16 genotyping controls. Genotypes were analyzed using a Taq-
Man 7900 HT (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands).
Sta­ti­sti­ca­l a­na­lyses
Power calculations were performed using the genetic power calculator of Pur-
cell et al. [28] (available at http://pngu.mgh.harvard.edu/»purcell/gpc/). Assuming 
a disease prevalence of 0.1, a genotype relative risk of 1.25 and 1.50, and an allele 
frequency of 0.75, the combined case-control sample afforded an estimated power 
of 0.77 at p < 0.05. The genotype frequencies were tested for Hardy–Weinberg equi-
librium by v2 analysis. Odds ratios and p-values for case-control analyses were cal-
culated using v2 tests. Adjustments for age sex­ and body mass index­ were done 
using logistic regression analyses. D9 and r­2 between the USF1 SNPs were calculated 
using Haploview.
Re­sults
We genotyped rs2073658 in all subjects from both cohorts. Geno-
type success rate was >98%, and the SNP was in Hardy–Weinberg 
equilibrium. In addition, we genotyped SNP rs3737787 in a subset 
of 590 subjects. In accordance with previous studies both SNPs 
were in perfect linkage disequilibrium (D9 = 1, r­2 = 1). The results 
of SNP rs2073658, which has the best credentials as a potential 
causal variant in USF1 [29], are presented in Table 3.
In the first case-control sample, prevalence of the major allele 
was higher in patients than in controls (75% versus 71%, odds ratio 
1.25, p = 0.018). In the second case-control sample, a similar fre-
quency difference and concomitant odds ratio were observed: 76% 
in patients versus 72% in control subjects, odds ratio 1.22. Although 
insuf­fi­cient power of the second case-control sample prevented 
this frequency difference to meet the threshold for statistical sig-
nificance (p = 0.16), the effect-size and -direction were identical to 
the first case-control sample and a combined analysis of both sam-
ples further strengthened the evidence for association (odds ratio 
1.23, p = 0.006). Adjustment for age and sex­ did not substantially 
Table­ 1
Clinical characteristics of case-control sample 1 (N = 1421)
Trait Patient group Control group
N (female/male) 501 (270a/230) 920 (354/557b)
Age-at-study (years) 70.7 § 9.9 47.8 § 12.7
Age-at-diagnosis (years) 57.6 § 14.4 —
BMI (kg/m2) 27.6 § 4.9 NA
HbA1c (%) 6.6 § 2.4 NA
HDL-cholesterol (mmol/L) 1.1 § 0.5 NA
Total cholesterol (mmol/L) 4.9 § 1.8 NA
Triacylglycerol (mmol/L) 1.7 § 1.1 NA
The data are presented as means § SD. HbA1c, haemoglobin A1c (glucose bound to 
haemoglobin); NA, not available.
 a Not available for one subject.
 b Not available for nine subjects.
Table­ 2
Clinical characteristics of case-control sample 2 (N = 590)
Trait Patient group Control group
n (female/male) 211 (67/144) 379 (157/222)
Age 59.7 § 6.5 57.8 § 7.3
BMI (kg/m2) 30.7 § 4.4 27.4 § 3.8b
Fasting glucose (mmol/L) 7.9 § 1.8 5.3 § 0.4
HDL-cholesterol (mmol/L) 1.0a § 0.3 1.3 § 0.4c
Total cholesterol (mmol/L) 5.1a § 1.0 5.2 § 0.9c
Triacylglycerol (mmol/L) 2.0a § 1.1 1.3 § 0.6c
The data are presented as means § SD.
 a Not available for 88 subjects.
 b Not available for 1 subject.
 c Not available for 94 subjects.
Table­ 3




DM2 (%) Control (%) Odds  
ratio
95% CI p-Value
Case-control sample 1 (N = 1421)
 AA 35 (7.2) 87 (9.6) 1
 AG 174 (35.6) 355 (39.1) 1.22 0.79–1.88 0.370
 GG 280 (57.3) 465 (51.3) 1.50 0.98–2.28 0.058
 A-allele 244 (24.9) 529 (29.2) 1
 G-allele 734 (75.1) 1285 (70.8) 1.25 1.04–1.48 0.018
Case-control sample 2 (N = 590)
 AA 13 (6.3) 28 (7.5) 1
 AG 74 (35.6) 152 (40.8) 1.05 0.51–2.14 0.896
 GG 121 (58.2) 193 (51.7) 1.35 0.67–2.71 0.396
 A-allele 100 (24.0) 208 (27.9) 1
 G-allele 316 (76.0) 538 (72.1) 1.22 0.93–1.61 0.155
Case-control sample 1+2 combined (N = 2011)
 AA 48 (6.9) 115 (9.0) 1
 AG 248 (35.6) 507 (39.6) 1.17 0.81–1.70 0.400
 GG 401 (57.5) 658 (51.4) 1.46 1.02–2.09 0.038
 A-allele 344 (24.7) 737 (28.8) 1
 G-allele 1050 (75.3) 1823 (71.2) 1.23 1.06–1.43 0.006
1396 subjects (98.2%) were genotyped successfully in case-control sample 1. 581 
subjects (98.5%) were genotyped successfully in case-control sample 2.
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influence the result (adjusted odds ratio 1.20, p = 0.02). Informa-
tion on BMI was not available for control subjects in sample 1. In 
sample 2, BMI was significantly higher in patients than control sub-
jects. To ex­plore the possibility that differences in allele frequency 
between patients and controls are primarily due to differences in 
body weight, we performed age-, sex­- and BMI-adjusted analyses 
in case-control sample 2. Adjustment for these traits only slightly 
reduced the effect-size in case-control sample 2 (odds ratio unad-
justed: 1.22; odds ratio age-, sex­- and BMI-adjusted: 1.15). This 
suggests that the observed differences in allele frequency are not 
primarily due to differences in body weight, age or sex­, but rather 
reflect a direct effect on type 2 diabetes.
Importantly, the increased risk for type 2 diabetes suscepti-
bility can be ascribed to the major allele, and its high frequency 
translates to a considerable population attributive risk of 14.5%. 
Together, these data indicate that the major allele of rs2073658 is 
associated with a modest but consistent increased risk for develop-
ing type 2 diabetes in Dutch Caucasians, with substantial impact at 
the population level.
Di­scussi­on
USF1 is a positional and functional candidate gene for type 2 
diabetes. The main finding of this study is that a polymorphism 
within the USF1-gene with strongest prior odds for association 
and best credentials for functional involvement (rs2073658) is 
associated with type 2 diabetes in an analysis with 2011 Dutch Cau-
casian subjects. The observed effect-size of the USF1 risk allele is 
modest (OR t 1.25), but consistent in the two independent Dutch 
case-control samples.
USF1 is a ubiquitously ex­pressed transcription factor of the 
basic helix­-loop-helix­ leucine zipper family and regulates the 
ex­pression of some 40 genes, several of them involved in lipid and 
glucose metabolism. USF1 mediates its transcriptional regulation 
through binding to E-box­ motifs in the promoter region of target 
genes with the consensus sequence CACGTG, either as homodimer 
but in most cases as a heterodimer with the related transcription 
factor USF2 [30].
USF1 was originally identified as a major susceptibility gene for 
FCHL, underlying the linkage signal on 1q21–23 in Finnish families 
with the disease [2]. Two polymorphisms in USF1, rs2073658 and 
rs3737787, in strong LD with each other, were the most strongly 
associated variants. Subsequent replication studies in various FCHL 
samples of distinct ethnicities implicated the same polymorphisms 
(or variants in tight LD) in the genetic background of FCHL [3,4,31]. 
Furthermore, differential ex­pression of USF1-regulated genes in 
adipose tissue from subjects with different allelic variants has 
been reported [29]. Complementary to these findings, significant 
associations with lipid traits, parameters of adipose tissue metab-
olism, and the metabolic syndrome in populations not specifically 
ascertained for FCHL, further ex­tended the potential significance 
of USF1 as a cardiovascular risk determinant [6,7,32–34]. Recent 
important data from a prospective follow up study demonstrate 
that USF1 risk alleles confer an approx­imately two fold increased 
risk to cardiovascular disease and all-cause mortality in women 
from two independent Finnish cohorts representative of the gen-
eral population [8]. These latter data provide important decisive 
evidence and illustrate how a gene originally identified in high risk 
families proves to be important also at the population level.
No amino acid changes have been detected in the USF1 gene that 
could functionally account for the observed associations. However, 
rs2073658 resides in a 20-bp DNA sequence that binds nuclear pro-
teins and possibly represents a transcriptional regulatory element 
[29]. In all studies to date rs2073658 and rs3737787 were among 
the strongest associated variants, suggesting that—irrespective of 
whether one of these SNP is a true etiological variant—they repre-
sent reliable markers for FCHL across populations of different eth-
nicity.
Triggered by the convincing results of USF1 variants in relation 
to FCHL and lipid traits, some research groups scrutinized the USF1 
gene for its potential contribution to inherited DM2 susceptibility. 
Four studies thus far investigated the potential association of USF1 
SNPs with type 2 diabetes or related traits [5,6,22,23]. Putt et al. 
were the first to genotype three USF1 SNPs in 800 male subjects 
and report haplotypic associations (comprising SNPs in tight LD 
with rs3737787 and rs2073658) with glucose levels during an oral 
glucose tolerance test [5]. In Hong Kong Chinese subjects three 
haplotype tagging SNPs, including rs3737787, were genotyped. 
Rs3737787 was associated with type 2 diabetes in 897 family cases 
from 179 families (40 of which showed 1q-linkage), but no associ-
ation was found in a second case-control cohort including 1383 
unrelated patients with type 2 diabetes and 454 control subjects 
[6]. Analyses in 744 French Caucasian patients with type 2 diabe-
tes and 731 normoglycemic controls revealed no significant asso-
ciation with any of 8 genotyped USF1 polymorphisms (strongest 
effect for rs2073658, p = 018) [22]. A large recent study in several 
populations with evidence of chromosome 1q linkage (N = 3726, 22 
genotyped variants) found no significant associations [23].
Although the USF1 risk allele in the present study confers only 
a modest risk to individuals carrying the risk variant, it may have a 
substantial impact at the population level. As much as »75% of sub-
jects carry the risk allele, which translates to a population attrib-
utable risk (PAR) of 14%. This means, that if the population were 
monomorphic for the protective allele, the prevalence of type 2 
diabetes would be 14% lower. This resembles the established type 
2 diabetes variant Pro12Ala in PPARc, which confers modest risk 
for the individual (OR = 1.25), but high risk at the population level 
(PAR = 25%) [35].
From our present study we conclude that the major allele 
of rs2073658 in the USF1 gene is associated with a modestly 
increased risk to develop DM2 in Dutch Caucasians, with consider-
able impact at the population level.
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